Financings in Brief: Urologix
This article was originally published in The Gray Sheet
Executive Summary
Urologix: Files with SEC for a proposed secondary offering of 1.5 mil. shares of common stock. The Minneapolis maker of minimally invasive devices for treatment of urological diseases received FDA approval Aug. 22 for its Targis microwave therapy device for treating benign prostatic hyperplasia ("The Gray Sheet" Sept. 1, p. 4), and plans to use proceeds from the offering to fund sales and marketing efforts, "to expand manufacturing capacity, and for working capital and other general corporate purposes," the firm says. Underwriters BT Alex. Brown, Dain Bosworth and PaineWebber hold an over-allotment option for 225,000 additional shares...
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.